Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 76

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 76
---
 enhance its ability to attract and retain exceptionally qualified individuals and agents and to encourage
them to acquire a proprietary interest in the company’s growth and performance. Competition for highly skilled personnel and agents
is often intense and NewGenIvf may incur significant costs or may not be successful in attracting, integrating, or retaining qualified
personnel and agents to fulfill NewGenIvf’s current or future needs. NewGenIvf believes that the granting of share-based awards
is of significant importance to NewGenIvf’s ability to attract and retain agents, key personnel and employees, and NewGenIvf will
continue to grant share-based awards in the future. In addition, NewGenIvf may, with the approval of its Compensation Committee and the
Board, revise the terms of, and increase the size of, its share incentive plan, to ensure that it is able to attract and retain agents,
key personnel and employees. On March 31, 2025, NewGenIvf’s Board approved certain amendments to its Share Incentive Plan, including
the increase of the size of the share incentive plan to 20% of the outstanding shares of the Company from time to time. As a result, NewGenIvf’s
expenses associated with share-based compensation may increase, which may have an adverse effect on NewGenIvf’s results of operations.
The amended share incentive plan is available as Exhibit 4.32.

Meanwhile, the retirement
or loss of certain specialists, scientific staff or other key personnel, the activities of competitors, the introduction of a competing
service that is perceived to be superior to the services provided by NewGenIvf, or other events which impact NewGenIvf’s reputation
could adversely affect NewGenIvf’s relationships with fertility specialists. For example, one specialist who was previously engaged
by NewGenIvf brought a lawsuit against NewGenIvf regarding disputed remuneration, which resulted in a settlement for NewGenIvf to compensate
the specialist with a sum of approximately US$98,000. Also, fertility specialists’ relationship with NewGenIvf could affect their
behaviors in recommending NewGenIvf’s services or referring patients to NewGenIvf, which could in turn adversely impact the number
of patients treated by NewGenIvf and adversely impact on its financial performance, market position and prospects.

In addition, the
perceived value of NewGenIvf’s solutions and its reputation may be negatively impacted if the services provided by fertility
specialists or other